ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

BridgeBio and Bayer side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BridgeBioBayer
studies on the registry481,694
open to participants now1160
phase 3 studies under way911
reach primary completion within a year235
programswith a study of their own in two years621

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBridgeBioBayer
Phase 100%19%
Phase 233%

Bayer: 8 of its 21 programs at phase 2

  1. AB-1005phase 2
  2. WRN Inhibitor RO7589831phase 2
  3. nurandociguatphase 2
  4. BAY 3401016phase 2
  5. BAY 3670549phase 2

and 3 more — sign in to see them all

38%
Phase 3

BridgeBio: 3 of its 6 programs at phase 3

  1. infigratinibphase 3
  2. encaleretphase 3
  3. ribitolphase 3
50%

Bayer: 4 of its 21 programs at phase 3

  1. elinzanetantphase 3
  2. sevabertinibphase 3
  3. bemdaneprocelphase 3
  4. aficamtenphase 3
19%
Approved, new studies

BridgeBio: 1 of its 6 programs at approved, new studies

  1. acoramidisapproved, new study
17%

Bayer: 5 of its 21 programs at approved, new studies

  1. finerenoneapproved, new study
  2. darolutamideapproved, new study
  3. Aspirinapproved, new study
  4. acoramidisapproved, new study
  5. Levonorgestrelapproved, new study
24%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
BridgeBio2 readouts · 2 phase 3··

BridgeBio, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. infigratinibphase 3 · Jan 0 · NCT06873035
·······

BridgeBio, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. ribitolphase 3 · Sep 0 · NCT05775848
·
Bayer10 readouts · 4 phase 3·

Bayer, Dec ’26: 1 program whose next study reaches primary completion

  1. BAY 3389934phase 1 · Dec 25 · NCT06854640

Bayer, Jan ’27: 1 program whose next study reaches primary completion

  1. elinzanetantphase 3 · Jan 22 · NCT07762287
·

Bayer, Mar ’27: 1 program whose next study reaches primary completion

  1. Aspirinapproved, new study · Mar 10 · NCT07652723

Bayer, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. finerenoneapproved, new study · Apr 10 · NCT05196035

Bayer, May ’27: 2 programs whose next study reaches primary completion

  1. nurandociguatphase 2 · May 7 · NCT07431294
  2. WRN Inhibitor RO7589831phase 2 · May 31 · NCT06004245
·

Bayer, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. darolutamideapproved, new study · Jul 30 · NCT05794906

Bayer, Aug ’27: 1 program whose next study reaches primary completion

  1. RAS/PI3K-alpha Inhibitor VVD-159642phase 1 · Aug 1 · NCT06804824

Bayer, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. acoramidisapproved, new study · Sep 17 · NCT07298044

Bayer, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sevabertinibphase 3 · Oct 28 · NCT06452277
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

BridgeBio

New programs 0

None

Reached a new phase 0

None

Study stopped 1

  • acoramidisphase 2 · terminated Oct 14“Study ended by the sponsor due to meeting Study Objectives” · NCT03536767

Primary completion later 0

None

Bayer

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 3 in all. A program counts in each condition its studies name most.

ConditionBridgeBioBayer
Amyloid Neuropathies, Familialboth · compare here

BridgeBio in Amyloid Neuropathies, Familial: 1 program

  1. acoramidisapproved, new study

Their studies: BridgeBio’s studies of Amyloid Neuropathies, Familial in search

Bayer in Amyloid Neuropathies, Familial: 1 program

  1. acoramidisapproved, new study

Their studies: Bayer’s studies of Amyloid Neuropathies, Familial in search

Amyloidosisboth · compare here

BridgeBio in Amyloidosis: 1 program

  1. acoramidisapproved, new study

Their studies: BridgeBio’s studies of Amyloidosis in search

Bayer in Amyloidosis: 1 program

  1. acoramidisapproved, new study

Their studies: Bayer’s studies of Amyloidosis in search

Amyloidosis, Hereditary, Transthyretin-Relatedboth · compare here

BridgeBio in Amyloidosis, Hereditary, Transthyretin-Related: 1 program

  1. acoramidisapproved, new study

Their studies: BridgeBio’s studies of Amyloidosis, Hereditary, Transthyretin-Related in search

Bayer in Amyloidosis, Hereditary, Transthyretin-Related: 1 program

  1. acoramidisapproved, new study

Their studies: Bayer’s studies of Amyloidosis, Hereditary, Transthyretin-Related in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetBridgeBioBayer
TTRacoramidisruleacoramidisrule
A target, or a pathogen for a vaccine, known for: BridgeBio 2 of 6 · Bayer 13 of 21 programs (15 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.